Insulin glargine: long-acting basal insulin analog for improved metabolic control

References

• Anderson JHJ, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R,. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1997;157:1249–55
   PubMed Web of Science ®Google Scholar
• Anderson JH, Jr., Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, DiMarchi R for the Multicenter Insulin Lispro Study Group. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 1997;46:265–70
   Google Scholar
• Lalli C, Ciofetta M, Del Sindaco P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999;22:468–77
   PubMed Web of Science ®Google Scholar
• Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999;22: 1501–6
   Google Scholar
• Nobels FR, Hermans MP, De Leeuw I. Insulin lispro (Humalog®), a novel fast-acting insulin analogue: guidelines for its practical use. Acta Clin Belg 1999;54:246–54
   PubMed Web of Science ®Google Scholar
• Texas Diabetes Council. Insulin algorithm for type 2 diabetes mellitus in children and adults. Available from http://www.tdh.state.tx.us/diabetes/pdf/algorithms/inst2.pdf. [Accessed 16 September 2003]
   Google Scholar
• Del Sindaco P, Ciofetta M, Lalli C, et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 1998;15:592–600
   PubMed Web of Science ®Google Scholar
• Rizza RA, Gerich JE, Haymond MW, Westland RE, Hall LD, Clemens AH, Service FJ. Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy. N Engl J Med 1980;303:1313–18
   PubMed Web of Science ®Google Scholar
• Zinman B. The physiologic replacement of insulin. An elusive goal. N Engl J Med 1989;321:363–70
   PubMed Web of Science ®Google Scholar
• Bolli GB, De Feo P, De Cosmo S, et al. Demonstration of a dawn phenomenon in normal human volunteers. Diabetes 1984;33:1150–3
   PubMed Web of Science ®Google Scholar
• Brange J, Owens DR, Kang S, Vølund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990;13:923–54
   PubMed Web of Science ®Google Scholar
• Heinemann L. Hypoglycemia and insulin analogues: is there a reduction in the incidence? J Diabetes Complications 1999;13:105–14
   PubMed Web of Science ®Google Scholar
• Bolli GB, Gottesman IS, Campbell PJ, et al. Glucose counterregulation and waning of insulin in the Somogyi phenomenon (posthypoglycemic hyperglycemia). N Engl J Med 1984;311:1214–19
   PubMed Web of Science ®Google Scholar
• Hirsch IB. Intensive treatment of type 1 diabetes. Med Clin North Am 1998;82:689–719
   PubMed Web of Science ®Google Scholar
• Galloway JA, Chance RE. Insulin agonist therapy: a challenge for the 1990s. Clin Ther 1990;12:460–72
   PubMed Web of Science ®Google Scholar
• Lauritzen T, Faber OK, Binder C. Variation in 125I-insulin absorption and blood glucose concentration. Diabetologia 1979;17: 291–5
   PubMed Web of Science ®Google Scholar
• Bähr M, Kolter T, Seipke G, Eckel J. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997;320: 259–65
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Schwartz SL, Clark CM, Jr., et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631–6
   PubMed Web of Science ®Google Scholar
• Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142–8
   PubMed Web of Science ®Google Scholar
• Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644–9
   PubMed Web of Science ®Google Scholar
• Ratner RE, Hirsch IB, Mecca TE, Wilson CA. Efficacy and safety of insulin glargine in subjects with type 1 diabetes: a 28 week randomized, NPH insulin-controlled trial. Diabetes 1999;48(Suppl 1):A120
   Google Scholar
• Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA for the US Study Group of Insulin Glargine in Type 1 Diabetes. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23: 639–43
   PubMed Web of Science ®Google Scholar
• Pieber TR, Eugene-Jolchine I, Derobert E for the European Study Group of HOE 901 in Type 1 Diabetes. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000;23:157–62
   Google Scholar
• Raskin P, Klaff L, Bergenstal R, Halle J-P, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23: 1666–71
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Park G, Zimmerman J for the US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000;23:1137–42
   Google Scholar
• Yki-Järvinen H, Dressler A, Ziemen M for the HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130–6
   Google Scholar
• Riddle MC, Rosenstock J, Gerich J on behalf of the Insulin Glargine 4002 Study Investigators. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26(11):forthcoming
   PubMed Web of Science ®Google Scholar